Resultados da pesquisa - ((((((drug de) OR (drug codes))) OR (((drug diet) OR (drug disease))))) OR (drug dna)) devel ther~

Pesquisas alternativas:
drug disease » lung disease (Expandir a Pesquisa), drug release (Expandir a Pesquisa)
drug codes » drug code (Expandir a Pesquisa), drug comes (Expandir a Pesquisa), drug copies (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa), level theory (Expandir a Pesquisa), develop them (Expandir a Pesquisa)
drug diet » drugs diet (Expandir a Pesquisa), drug does (Expandir a Pesquisa)
drug de » drug dose (Expandir a Pesquisa)

1

Lactobacilli with superoxide dismutase-like or catalase activity are more effective in alleviating inflammation in an inflammatory bowel disease mouse model

Lactobacilli with superoxide dismutase-like or catalase activity are more effective in alleviating inflammation in an inflammatory bowel disease mouse model

Por Tomusiak-Plebanek, Anna, Heczko, Piotr, Skowron, Beata, Baranowska, Agnieszka, Okoń, Krzysztof, Thor, Piotr J, Strus, Magdalena
Publicado no Drug Des Devel Ther (2018)

“... and check which of them play a crucial role in alleviating intestinal inflammation. METHODS: We selected two...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

2

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date

Por Squitieri, Ferdinando, de Yebenes, Justo Garcia
Publicado no Drug Des Devel Ther (2015)

“... it might be a neuroprotective and disease-modifying drug. Data from ongoing clinical trials of pridopidine...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

3

Defective DNA repair mechanisms in prostate cancer: impact of olaparib

Defective DNA repair mechanisms in prostate cancer: impact of olaparib

Por De Felice, Francesca, Tombolini, Vincenzo, Marampon, Francesco, Musella, Angela, Marchetti, Claudia
Publicado no Drug Des Devel Ther (2017)

“... is an oral PARP inhibitor that blocks DNA repair pathway and coupled with BRCA mutated-disease results...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

4

Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms

Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms

Por Scheinberg, Morton, Pott Júnior, Henrique, Macêdo, Eduardo de Almeida, Bocchi de Oliveira, Monalisa Fernanda, Ecclissato, Christina, Amazonas, Roberto Bleuel
Publicado no Drug Des Devel Ther (2018)

“... suited to relieve pain in patients with osteoarticular diseases and dyspeptic symptoms. METHODS: Patients...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

5

Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii

Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii

Por de Leeuw, Erik PH
Publicado em 2014

“... compound that targets Lipid II is described that acts against multi-drug resistant isolates of A. baumannii...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

6

The role of taxanes in triple-negative breast cancer: literature review

The role of taxanes in triple-negative breast cancer: literature review

Por Mustacchi, Giorgio, De Laurentiis, Michelino
Publicado no Drug Des Devel Ther (2015)

“... by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

7

Hologram quantitative structure–activity relationship and comparative molecular field analysis studies within a series of tricyclic phthalimide HIV-1 integrase inhibitors

Hologram quantitative structure–activity relationship and comparative molecular field analysis studies within a series of tricyclic phthalimide HIV-1 integrase inhibitors

Por de Oliveira Magalhães, Uiaran, de Souza, Alessandra Mendonça Teles, Albuquerque, Magaly Girão, de Brito, Monique Araújo, Bello, Murilo Lamim, Cabral, Lucio Mendes, Rodrigues, Carlos Rangel
Publicado em 2013

“... immunodeficiency virus (HIV). Treatment with antiretroviral drugs is the best option for viral suppression...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

8

Antibiotic-modifying activity of riachin, a non-cyanogenic cyanoglycoside extracted from Bauhinia pentandra

Antibiotic-modifying activity of riachin, a non-cyanogenic cyanoglycoside extracted from Bauhinia pentandra

Por de Farias, Pablo Antonio Maia, Figueredo, Fernando Gomes, Lucas, Aline Maria Brito, de Moura, Rafael Barbosa, Coutinho, Henrique Douglas Melo, da Silva, Tania Maria Sarmento, Martin, Ana Luiza de Aguiar Rocha, Fonteles, Marta Maria de França
Publicado no Drug Des Devel Ther (2015)

“... any strain (P>0.05). However, when combined with conventional antibiotics, it showed drug-modifying...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

9

Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays

Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays

Por Rezende, Vinicius Marcondes, Rivellis, Ariane, Novaes, Mafalda Megumi Yoshinaga, de Alencar Fisher Chamone, Dalton, Bendit, Israel
Publicado em 2013

“... and Drug Administration and Brazilian National Health Surveillance Agency within the range of 0.500–10.0 μg...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

10

Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy

Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy

Por Ruiz de Garibay, Aritz Pérez, Delgado, Diego, del Pozo-Rodríguez, Ana, Solinís, María Ángeles, Gascón, Alicia Rodríguez
Publicado em 2012

“... for the treatment of Fabry disease (FD). The objective of the present study was to demonstrate the potential...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

11

Synthetic biology for pharmaceutical drug discovery

Synthetic biology for pharmaceutical drug discovery

Por Trosset, Jean-Yves, Carbonell, Pablo
Publicado no Drug Des Devel Ther (2015)

“... of artemisinin by microorganisms, a tour de force in protein and metabolic engineering. Today, synthetic cells...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

12

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis

Por Mazo, Daniel FC, de Oliveira, Marcelo G, Pereira, Isabel VA, Cogliati, Bruno, Stefano, José T, de Souza, Gabriela FP, Rabelo, Fabíola, Lima, Fabiana R, Alves, Venâncio A Ferreira, Carrilho, Flair J, de Oliveira, Claudia PMS
Publicado em 2013

“... diet and exposed to diethylnitrosamine for 8 weeks. The rats were divided into three groups: SNAC...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

13

Changing the face of hepatitis C management – the design and development of sofosbuvir

Changing the face of hepatitis C management – the design and development of sofosbuvir

Por Noell, Bennett C, Besur, Siddesh V, deLemos, Andrew S
Publicado no Drug Des Devel Ther (2015)

“... disease or on dialysis must await dosing recommendations. Sofosbuvir-based regimens appear to be well...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

14

Comment on a meta-analysis comparing hepatic resection or transarterial chemoembolization as initial treatment for hepatocellular carcinoma

Comment on a meta-analysis comparing hepatic resection or transarterial chemoembolization as initial treatment for hepatocellular carcinoma

Por Zhong, Jian-Hong, Xiang, Bang-De, Li, Le-Qun
Publicado no Drug Des Devel Ther (2015)

Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

15

Aminaphtone in the control of gingival bleeding in children

Aminaphtone in the control of gingival bleeding in children

Por Pereira de Godoy, José Maria, Macedo Paizan, Mara Lucia
Publicado em 2014

“... of identical pills of either aminaphtone or placebo were produced and coded with unique numbers...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

16

Disease-modifying drugs in Alzheimer’s disease

Disease-modifying drugs in Alzheimer’s disease

Por Ghezzi, Laura, Scarpini, Elio, Galimberti, Daniela
Publicado em 2013

“... on disease-modifying drugs aiming to interfere with the amyloid beta peptide, including vaccination, passive...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

17

Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection

Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection

Por Mascellino, Maria Teresa, Porowska, Barbara, De Angelis, Massimiliano, Oliva, Alessandra
Publicado no Drug Des Devel Ther (2017)

“... diseases, the number of previous antibiotic treatments, differences in bacterial virulence in individuals...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

18

The impact of lipocalin-type-prostaglandin-D-synthase as a predictor of kidney disease in patients with type 2 diabetes

The impact of lipocalin-type-prostaglandin-D-synthase as a predictor of kidney disease in patients with type 2 diabetes

Por Bacci, Marcelo Rodrigues, Cavallari, Marina Romera, de Rozier-Alves, Ross Martin, Alves, Beatriz da Costa Aguiar, Fonseca, Fernando Luiz Affonso
Publicado no Drug Des Devel Ther (2015)

“... kidney disease as well as risk factors for cardiovascular events. In recent years, lipocalin-type...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

19

A novel small-molecule inhibitor of HIV-1 entry

A novel small-molecule inhibitor of HIV-1 entry

Por Heredia, Alonso, Latinovic, Olga S, Barbault, Florent, de Leeuw, Erik PH
Publicado no Drug Des Devel Ther (2015)

“... options due to HIV-1 resistance, side effects, or drug costs. Further, it is likely that current drugs...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

20

Analysis of HSP90-related folds with MED-SuMo classification approach

Analysis of HSP90-related folds with MED-SuMo classification approach

Por Doppelt-Azeroual, Olivia, Moriaud, Fabrice, Delfaud, François, de Brevern, Alexandre G
Publicado em 2009

“... three types of proteins (HSP90, topoisomerase VI, and BCK) which all bind the drug radicicol....”
Obter o texto integral
Obter o texto integral

Artigo

1
2
3
4
5
6
7
8
9
10
11
Seguinte
[35]